Skip to main content
. Author manuscript; available in PMC: 2024 Apr 15.
Published in final edited form as: Psychopharmacology (Berl). 2020 May 22;237(8):2367–2380. doi: 10.1007/s00213-020-05540-w

Table 2.

Adverse events: number of enrolled subjects experiencing each event

Event Pioglitazone (n = 8) Placebo (n = 8)
Abdominal pain 0 1
Abnormal glucose 1 0
Abnormal platelet count 1 0
Acne 0 1
Anxiety 0 1
Asthma exacerbation by viral infection 1a 0
Bloating 1 0
Blood in stool 0 1
Blurred vision 0 1
Buzzed 1 0
Chills 0 1
Cold-like symptoms 0 3
Dark urine 0 1
Deep vein thrombosis 1a 0
Elevated aspartate aminotransferase 1 0
Elevated creatine kinase 5b 1
Fatigue 0 1
Fever 1 0
Frequent urination 0 1
Headache 2 4
Irritability 0 1
Itching 1 1
Lightheaded 1 1
Loss of appetite 2 0
Low red blood count/hemoglobin A1C 1 0
Muscle aches 1 3
Muscle tightness 0 1
Nausea 1 2
Neck pain 1 0
Pain 2 0
Pain in extremity 1 0
Phlebitis 0 1
Sinus pain 0 2
Sleepiness 1 1
Sore throat 2 2
Stomach pain 1 1
Tiredness 5 5
Toothache 1 3
Trouble sleeping 1 0
a

Reported as a serious adverse event

b

One occurrence reported as a serious adverse event